Treatment and Outcomes of Crohn’s Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007 to 2023
Clinical Gastroenterology and Hepatology · 2026-11 · 24 (11) · 3089-3099
DOI: 10.1016/j.cgh.2026.04.006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-11. Verfasst von Dhruv Ahuja und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Indira Gandhi Hospital, New Delhi, India. Hauptthemen laut MEDLINE: Crohn Disease, Colitis, Ulcerative. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NCCDPHP CDC HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
BACKGROUND & AIMS: We examined treatment and outcomes of inflammatory bowel diseases (IBDs) in a contemporary and diverse cohort of adults with newly diagnosed IBD in a large, commercially insured United States population. METHODS: Using an administrative claims database (OptumLabs Data Warehouse), we created an inception cohort of physician-diagnosed IBD between 2007 and 2023. We examined cumulative incidence of hospitalization, surgery, safety events, and medication use in patients with Crohn's disease (CD) and ulcerative colitis (UC). RESULTS: Among 3044 adults with newly diagnosed CD (age at diagnosis, 39 ± 15 years; 47% male; 83% White, 7.5% Black, and 7.1% Hispanic patients) followed over a mean 4.3 ± 3.1 years, 5-year risk of IBD-related hospitalization, major surgery, and serious infections was 16%, 12%, and 13%, respectively, with no consistent racial and ethnic, age, or sex differences. In patients diagnosed between 2019 and 2023, 1-year cumulative use of corticosteroids and advanced therapy was 44% (22% with ≥2 courses) and 53%, respectively, without significant racial and ethnic, age, or sex differences. Among 3893 patients with newly diagnosed UC (age at diagnosis, 41 ± 14 years; 52% male; 80% White, 7.2% Black, and 8.2% Hispanic patients) followed over 4.2 ± 3.0 years, 5-year risk of IBD-related hospitalization, colectomy, and serious infection was 11%, 6%, and 10%, respectively, with lower risk in Hispanic patients (vs White patients). In patients diagnosed between 2019 and 2023, 1-year cumulative use of corticosteroids and advanced therapy was 47% (26% with ≥2 courses) and 27%, respectively, with earlier initiation of advanced therapies in more recent time periods, and with lower utilization of advanced therapies in Hispanic patients. CONCLUSIONS: In a contemporary and diverse cohort of commercially insured adults with newly diagnosed IBD in the United States, excess corticosteroid use is decreasing in recent era, along with early initiation of advanced therapies. No consistent racial and ethnic, age, or sex differences were identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Indira Gandhi Hospital, New Delhi, India.
- Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California; Department of Gastroenterology, Samsung Kangbuk Hospital, Sungkyunkwan University School of Medicine, Seoul…
- Division of Biostatistics and Bioinformatics, Herbert Wertheim School of Public Health, University of California San Diego, La Jolla, California.
- Division of Gastroenterology, Department of Medicine, University of California San Diego, La Jolla, California.
- Division of Gastroenterology, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
- Department of Medicine and Biostatistics and Epidemiology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Division of Gastroenter…
Förderung
- NIDDK NIH HHS
- NCCDPHP CDC HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Ahuja, D., Park, S. K., Qi, Y., Patel, S. B., Jairath, V., Xu, R., Boland, B. S., Lewis, J. D., Kappelman, M. D., Goodwin, S. W., & Singh, S. (2026). Treatment and Outcomes of Crohn’s Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007 to 2023. Clinical Gastroenterology and Hepatology, 24(11), 3089-3099. https://doi.org/10.1016/j.cgh.2026.04.006
Vancouver
Ahuja D, Park SK, Qi Y, Patel SB, Jairath V, Xu R, et al. Treatment and Outcomes of Crohn’s Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007 to 2023. Clinical Gastroenterology and Hepatology. 2026;24(11):3089-3099. doi:10.1016/j.cgh.2026.04.006
BibTeX
@article{Ahuja2026,
author = {Ahuja, Dhruv and Park, Soo-Kyung and Qi, Yuchen and Patel, Sagar B and Jairath, Vipul and Xu, Ronghui and Boland, Brigid S and Lewis, James D and Kappelman, Michael D and Goodwin, Shane W and Singh, Siddharth},
title = {Treatment and Outcomes of Crohn’s Disease and Ulcerative Colitis in Newly Diagnosed Adults in the United States, 2007 to 2023},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {11},
pages = {3089--3099},
doi = {10.1016/j.cgh.2026.04.006}
}
EUVIMED